Supplementary Results

This work
Escherichia coli DH10B and BL21(DE3) were purchased from Invitrogen.
Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs. Synthetic oligonucleotides were purchased from Invitrogen.
Polymerase chain reactions were carried out by using Pfu DNA polymerase from Strategene. Bacterial strains and plasmids used during this study are summarized in Table 3 . Isolation of chromosomal and plasmid DNA was performed by standard protocols 11, 12 . The plasmids pET28a(+) and pET29b(+)
were purchased from Novagen. His-Bind nickel chelate chromatography resin was obtained from Novagen. All chemicals and materials used for assays were purchased from Sigma-Aldrich. NMR spectra were recorded at 300 K using
Bruker DPX-400, Avance 400 QNP and Avance 500 spectrometers. 
Construction and screening of genomic cosmid library:
The genomic DNA of Streptomyces sp. 88-682 wild type was partially digested with BamHI, dephosphorylated by alkaline phosphatase SAP and ligated to the prepared SuperCos 1 (Stratagene) vector without fractionation. E.
coli XL1-Blue MR strain and Gigapack III XL packaging extract (Stratagene)
were used for library construction according to the manufacturer's instructions.
About 2,000 colonies were screened by colony-hybridization with a 1,926 bp
NdeI-EcoRI DIG-labeled probe containing a complete tmn16 gene recovered from pYH94. Three overlapping positive cosmids were obtained by restriction enzyme analysis.
Sequencing and annotation of the RK-682 biosynthetic gene cluster:
One of the overlapping positive cosmids (cosmid 6. 
Culture conditions:
Streptomyces sp. RK-682 wild type and mutants were grown in TSBY liquid medium (3% tryptone soy broth, 10.3% sucrose, 0.5% yeast extract) for isolation of chromosomal DNA, and TWM medium (0.5% glucose, 1% sucrose, 0.5% tryptone, 0.25% yeast extract, 0.0036% EDTA, 2% agar, pH 7.1) for RK-682 production. For liquid culture, the strains were grown at 28°C and 200 rpm on a rotary incubator and harvested after 2 days, and for solid culture, the strains were grown at 28°C for 6 days. E. coli strains were cultured in 2×TY medium (1.6% tryptone, 1% yeast extract, 0.5% NaCl) at 37°C with the appropriate antibiotic selection at a final concentration of 100 μg ml -1 carbenicillin, 50 μg ml -1 apramycin or 25 μg ml -1 chloramphenicol.
Gene disruption, complementation and heterologous expression:
The constructs used in this study for gene disruption, complementation and heterologous expression are summarized in the Supplementary Table 3 .
The constructs were introduced into Streptomyces sp. 88-682 by conjugation using donor strain ET12657/pUZ8002 on 20ml of SFM plates (2% mannitol, 2% soya flour, 2% agar). After incubating at 30°C for 8 hours, exconjugants were selected with 50 μg ml -1 apramycin or 25 μg ml -1 thiostrepton and 25 μg and pYH218 were introduced into ΔrkD mutant, respectively, by conjugation through the procedure described above, and selected with 50 μg ml 
Production, isolation and analysis of RK-682:
To assess RK-682 production, each plate containing 10 ml TWM medium was inoculated with the same amount of seed culture and grown as described above. After cultivation for 6 days, the whole plate culture was extracted with 40 ml ethyl acetate. The organic phase was evaporated to dryness under reduced pressure using a Speed-Vac. The residue was redissolved in 800 μl 
Construction of gene disruption plasmids:
To disrupt rkA by in-frame deletion, a 6,070 bp SphI fragment that contains rkA from cosmid 6.3 was cloned into the unique SphI site of pJTU412, an E. coli-Streptomyces shuttle vector derived from pHZ1358 5, 6 , to create pYH213. The resultant plasmid was digested with SacI and re-ligated itself to produce pYH214, in which a 1,626 bp fragment between two SacI sites in rkA had been deleted in-frame. To verify the in-frame deletion in the gene disruption construct and mutant, the following pair of primers was used:
RK682A-CP1: 5'-CCG AAG CTG CGA CGT GCA C-5', RK682A-CP2: 5'-CAC CGA GTC GAT GCC GTA GTC-3'.
To disrupt rkD by in-frame deletion, two fragments used for homologous recombination were amplified from cosmid 6.3 by PCR using the following primers rkD-L1: 5'-GGG AGA TCT GGC GTC CGT GGT GGC CGG G-3' (BglII site is underlined), and rkD-L2: 5'-GAC GGT ACC GGG TGA CGG ACT CAT GTG CGC GG-3' (KpnI site is underlined), rkD-R1: 5'-TCC GGT ACC GCC CTG GAG CGC GCA TGA C-3' (KpnI site is underlined) and rkD-R2: 5'-GGA AAA GCT TGG TGC GCA GGG TGA GTT GGG-3' (HindIII site is underlined).
After digestion with appropriate restriction enzymes, these two fragments were cloned into the Streptomyces-E. coli shuttle vector pJTU412 5, 6 
treated with
BglII and HindIII and via three-way ligation used to create construct pYH230.
To verify the in-frame deletion in construct and mutant, a pair of primers was designed as follows for PCR and sequencing, rkD-CP1: 5'-ACG GGG TGT CCG AGG T-3' and rkD-CP2: 5'-TGG ACT GGC CGG TGA C-3'.
To disrupt rkG by in-frame deletion, two fragments used for homologous recombination were amplified from cosmid 6.3 by PCR using the following primers rkG-L1: 5'-GCC CAT ATG CCC GTG GTG ACC GTC GC-3' (NdeI site is underlined), rkG-L2: 5'-GCC CTG CAG GGC GGC CGT GGC-3' (PstI site is underlined), rkG-R1: 5'-GCG CTG CAG GCC CCC GCG TGA C-3' (PstI site is underlined) and rkG-R2: 5'-CGT AAG CTT CTG GGT CAC CGA CCC CGG-3'
(HindIII site is underlined). After digestion with appropriate restriction enzymes, these two fragments were cloned into Streptomyces-E. coli shuttle vector To disrupt rkH by in-frame deletion, two fragments used for homologous recombination were amplified from cosmid 6.3 by PCR using the following primers rkH-L1: 5'-GAA CAT ATG CAG GGT CTT GGG GCC-3' (NdeI site is underlined), rkH-L2: 5'-GTC GAA TTC TCC TCG GAG GTC TGA G-3' (EcoRI site is underlined), rkH-R1: 5'-GCG GAA TTC GAG CTG AGT GGT CAC GG-3' (EcoRI site is underlined) and rkH-R2: 5'-GGT AAG CTT GCG GAT CGC GCC GGG-3' (HindIII site is underlined). After digestion with appropriate restriction enzymes, these two fragments were cloned into Streptomyces-E.
coli shuttle vector pYH7 5-7 treated with NdeI and HindIII and by three-way ligation used to create construct pYH280. To verify the in-frame deletion in construct and mutant, a pair of primers was designed as follows for PCR and sequencing, rkH-CP1: 5'-TTG CGC CAG CGG CGG TAG AT-3' and rkH-CP2:
5'-TTC GGA GGT TCC CGC AGG GTG T-3'.
Construction of protein expression plasmids:
Amplification (NdeI site is underlined) and RkC-EPC: 5'-TGA GAA TTC CAT GTG CGC GGT CCT TCC-3' (EcoRI site is underlined) was cloned into similarly-digested pET29b(+) to yield a construct pYH252 with a C-terminal hexahistidine tag.
The construction of genes encoding Tmn16 and Tmn7a has been previously described 9 .
Construction of heterologous expression plasmids:
To construct a heterologous expression plasmid containing contiguous genes rkB-rkE, a PCR product was obtained by using primers RK682B-EP1and RK682E-EP2, then cloned into the integrative vector pCJR124 (previously treated with NdeI and EcoRI) to yield pYH264, in which rkB-rkE were under the control of the PactII-ORF4 promoter.
To construct a heterologous expression plasmid containing contiguous genes rkA-rkE, a PCR product was obtained by using primers RK682A-EP1 and RK682G-EP2, then cloned into integrative vector pCJR124 (previously treated with NdeI and EcoRI) to yield pYH266, in which rkA-rkE were under the control of the PactII-ORF4 promoter.
To construct a heterologous co-expression plasmid containing contiguous genes rkA-rkE and tmn7a, the tmn7a was first cloned into the NdeI-EcoRI sites of pCJR124 by PCR using primers Tmn7a-EP1: 5'-CAC CAT ATG ACG ACC ATC GAC GAT CTT G-3' (NdeI site is underlined) and Tmn7a-EP2: 5'-AGC GAA TTC TTA TCA CGC CGC GAC CGC CGC C-3' (EcoRI site is underlined).
The PCR product of tmn7a with promoter PactII-ORF4 amplified with primers Pact-tmn7a-P1: 5'-TAC GCT AGC TAG TCC ACT GCC TCT C-3' (NheI site is underlined) and Pact-tmn7a-P2: 5'-GAC GCT AGC CTA TGA ATT CTT ATC AC-3' (NheI site is underlined) was then cloned into the unique NheI site of pYH266 to yield pYH273, in which rkA-rkE and tmn7a were under the control of two independent PactII-ORF4 promoters.
To construct a heterologous expression plasmid containing contiguous genes rkA-rkF, a PCR product was obtained by using primers RK682A-EP1 and RK682F-EP2, then cloned into the integrative vector pCJR124 (previously treated with NdeI and EcoRI) to yield pYH281, in which rkA-rkF were under the control of the PactII-ORF4 promoter.
To construct a heterologous expression plasmid containing contiguous genes rkA-rkG, a PCR product was obtained by using primers RK682A-EP1 and RK682G-EP2, then cloned into the integrative vector pCJR124 (previously treated with NdeI and EcoRI) to yield pYH282, in which rkA-rkG were under the control of the PactII-ORF4 promoter.
To construct a heterologous co-expression plasmid containing contiguous genes rkA-rkF and rkH-rkI, rkH-rkI was first cloned into the NdeI-EcoRI sites of pCJR124 by PCR using primers rkH-I-P1: 5'-CAT CAT ATG ACC ACT CAG CTC GAA CC-3' (NdeI site is underlined) and rkH-I-P2: 5'-CGG GAA TTC TAC CGG GGT GCG GGG-3' (EcoRI site is underlined). The PCR product of rkH-rkI with the promoter PactII-ORF4 was amplified with primers NheI-P1:
5'-TAC GCT AGC TAG TCC ACT GCC TC-3' (NheI site is underlined) and NheI-P2: 5'-CGC GCT AGC CGA TTC ATT AAT GC-3' (NheI site is underlined)
was then cloned into the unique NheI site of pYH281 to yield pYH284, in which rkA-rkF and rkH-rkI were under the control of two independent PactII-ORF4
promoters.
To construct a heterologous co-expression plasmid containing contiguous genes rkA-rkG and rkH-rkI, the PCR product of rkH-rkI with promoter PactII-ORF4 was amplified with primers NheI-P1 and NheI-P2 and was cloned into the unique NheI site of pYH282 to yield pYH285, in which rkA-rkG and rkH-rkI were under the control of two independent PactII-ORF4 promoters.
Construction of complementation plasmids:
The entire rkD gene was cloned as an NdeI-EcoRI fragment from RkD expression plasmid pYH228 and placed under the control of the PermE* promoter in the integrative vector pIB139 and PactII-ORF4 promoter in the integrative vector pCJR124, respectively, produced pYH217 and pYH218.
Expression and purification of proteins:
For expression and purification of RkA, apo-ACP(RkC), RkD and RkE, the expression plasmids pYH225, pYH258, pYH228 and pYH229 were introduced, respectively, into E. coli strain BL21(DE3) and grown in 2×TY medium supplemented with kanamycin (50 μg ml before induction was applied when expressing holo-RkC. Tmn7a and Tmn16
were expressed and purified as previously described 9 .
(Thermo Finnigan LCQ run by Hewlett Packard 1100 liquid chromatograph) was operated in the positive ion mode, scanning from 600 to 2,000 m/z. The mass spectrometric data were processed and deconvoluted using the Bioworks software (Thermo Finnigan). Fig. 15 ). Fig. 18 ). 
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